Home › Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
 

Keywords :   


Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015

2015-09-18 21:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the companys investigational beta-lactamase inhibitor for the treatment, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), of complicated intra-abdominal infections, met its primary endpoint, and that Merck is now initiating pivotal Phase 3 studies. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Ian McConnell, (973) 901-5722orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results study presented phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05'Time running out' plea over shipyard's future
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05China's Nio unveils Tesla Model Y rival
16.05Could the US economy be doing too well?
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
More »